These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 33722297)

  • 1. Underlying mechanisms and drug intervention strategies for the tumour microenvironment.
    Li H; Zhou L; Zhou J; Li Q; Ji Q
    J Exp Clin Cancer Res; 2021 Mar; 40(1):97. PubMed ID: 33722297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of macrophage in regulating tumour microenvironment and the strategies for reprogramming tumour-associated macrophages in antitumour therapy.
    Xu L; Xie X; Luo Y
    Eur J Cell Biol; 2021 Mar; 100(2):151153. PubMed ID: 33476912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Taking a Full Snapshot of Cancer Biology: Deciphering the Tumor Microenvironment for Effective Cancer Therapy in the Oncology Clinic.
    Dzobo K
    OMICS; 2020 Apr; 24(4):175-179. PubMed ID: 32176591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy.
    Pitt JM; Marabelle A; Eggermont A; Soria JC; Kroemer G; Zitvogel L
    Ann Oncol; 2016 Aug; 27(8):1482-92. PubMed ID: 27069014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fine-Tuning the Tumour Microenvironment: Current Perspectives on the Mechanisms of Tumour Immunosuppression.
    Armitage JD; Newnes HV; McDonnell A; Bosco A; Waithman J
    Cells; 2021 Jan; 10(1):. PubMed ID: 33401460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting cancer-related inflammation in the era of immunotherapy.
    Nakamura K; Smyth MJ
    Immunol Cell Biol; 2017 Apr; 95(4):325-332. PubMed ID: 27999432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting tumour microenvironment by tyrosine kinase inhibitor.
    Tan HY; Wang N; Lam W; Guo W; Feng Y; Cheng YC
    Mol Cancer; 2018 Feb; 17(1):43. PubMed ID: 29455663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Roles of CD38 and CD157 in the Solid Tumor Microenvironment and Cancer Immunotherapy.
    Wo YJ; Gan ASP; Lim X; Tay ISY; Lim S; Lim JCT; Yeong JPS
    Cells; 2019 Dec; 9(1):. PubMed ID: 31861847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multimodal Molecular Imaging of the Tumour Microenvironment.
    Foray C; Barca C; Backhaus P; Schelhaas S; Winkeler A; Viel T; Schäfers M; Grauer O; Jacobs AH; Zinnhardt B
    Adv Exp Med Biol; 2020; 1225():71-87. PubMed ID: 32030648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reshaping immunometabolism in the tumour microenvironment to improve cancer immunotherapy.
    Chen S; Duan H; Sun G
    Biomed Pharmacother; 2023 Aug; 164():114963. PubMed ID: 37269814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The updated landscape of tumor microenvironment and drug repurposing.
    Jin MZ; Jin WL
    Signal Transduct Target Ther; 2020 Aug; 5(1):166. PubMed ID: 32843638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exosomes: Critical Mediators of Tumour Microenvironment Reprogramming.
    Malla RR; Shailender G; Kamal MA
    Curr Med Chem; 2021; 28(39):8182-8202. PubMed ID: 33334279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges.
    Martin JD; Cabral H; Stylianopoulos T; Jain RK
    Nat Rev Clin Oncol; 2020 Apr; 17(4):251-266. PubMed ID: 32034288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy.
    Bader JE; Voss K; Rathmell JC
    Mol Cell; 2020 Jun; 78(6):1019-1033. PubMed ID: 32559423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The interactions of paclitaxel with tumour microenvironment.
    Yu DL; Lou ZP; Ma FY; Najafi M
    Int Immunopharmacol; 2022 Apr; 105():108555. PubMed ID: 35121223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The tumour microenvironment and metabolism in renal cell carcinoma targeted or immune therapy.
    Lai Y; Tang F; Huang Y; He C; Chen C; Zhao J; Wu W; He Z
    J Cell Physiol; 2021 Mar; 236(3):1616-1627. PubMed ID: 32783202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New opportunities for immunomodulation of the tumour microenvironment using chemical tools.
    Su JY; Li WH; Li YM
    Chem Soc Rev; 2022 Sep; 51(18):7944-7970. PubMed ID: 35996977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hijacked Immune Cells in the Tumor Microenvironment: Molecular Mechanisms of Immunosuppression and Cues to Improve T Cell-Based Immunotherapy of Solid Tumors.
    Balta E; Wabnitz GH; Samstag Y
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-talk of four types of RNA modification writers defines tumor microenvironment and pharmacogenomic landscape in colorectal cancer.
    Chen H; Yao J; Bao R; Dong Y; Zhang T; Du Y; Wang G; Ni D; Xun Z; Niu X; Ye Y; Li HB
    Mol Cancer; 2021 Feb; 20(1):29. PubMed ID: 33557837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crosstalk among m
    Zhang F; Liu H; Duan M; Wang G; Zhang Z; Wang Y; Qian Y; Yang Z; Jiang X
    J Hematol Oncol; 2022 Jul; 15(1):84. PubMed ID: 35794625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.